A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Exclusion Criteria

• •1. History of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease
• •2. Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis
• •3. Has received any therapeutic agent directly targeted to IL-17within 6 months of the first administration of study agent
• •4. Has received any therapeutic agent directly targeted toTNF-a within 3 months of the first administration of study agent
• •5. Has received any conventional therapeutic agent within 1 months of the first administration of study agent
• •6. Has received any topic therapeutic agent within 2 weeks of the first administration of study agent